D&O Ongoing Disclosure – Multiple

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:3 September 2021
Date of last disclosure: 21 May 2021
Director or senior manager giving disclosure
Full name(s):
Gordon Neil MacLeod
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Executive
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
(1)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Beneficial owner subject to the terms of
the Ryman Healthcare Limited Employee
Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
255,237
Number held in class after acquisition or disposal:
178,395
Current registered holder(s):
David William Kerr & Warren James Bell
as custodian for the Ryman Healthcare
Limited Employee Share Scheme (held
as bare trustees)
Registered holder(s) once transfers are registered:
N/A
(2)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
211,923
Number held in class after acquisition or disposal:
222,654
Current registered holder(s):
Gordon Neil MacLeod
Registered holder(s) once transfers are registered:
N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure-
(1)
Date of transaction:
27 August 2021
Nature of transaction:
Transfer of legal title to 76,842 ordinary
shares subject to the terms of the Ryman
Healthcare Limited Employee Share
Scheme, from David William Kerr &
Warren James Bell as custodian (as bare
trustees) for the Ryman Healthcare
Limited Employee Share Scheme to
Gordon Neil MacLeod, in accordance
with such terms
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
N/A
Number of financial products to which the transaction related: 76,842
(2)
Date of transaction:
27 August 2021
Nature of transaction:
On market sale, solely to facilitate the
repayment by Mr MacLeod of loans owed
to Ryman under the Ryman Healthcare
Limited Employee Share Scheme (with
Mr MacLeod retaining none of the
proceeds of sale). All other shares
vesting at the same time have been
retained by Mr MacLeod.
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$967,005.60 (being $14.627 per share)
Number of financial products to which the transaction related: 66,111
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
3 September 2021
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:3 September 2021
Date of last disclosure: 8 September 2020
Director or senior manager giving disclosure
Full name(s):
David Bennett
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
(1)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Beneficial owner subject to the terms of
the Ryman Healthcare Limited Employee
Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
119,934
Number held in class after acquisition or disposal:
140,330
Current registered holder(s):
David William Kerr & Warren James Bell
as custodian for the Ryman Healthcare
Limited Employee Share Scheme (held
as bare trustees)
Registered holder(s) once transfers are registered:
N/A
(2)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
32,724
Number held in class after acquisition or disposal:
32,724
Current registered holder(s):
David Bennett
Registered holder(s) once transfers are registered:
N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Three
Details of transactions requiring disclosure-
(1)
Date of transaction:
27 August 2021
Nature of transaction:
Transfer of legal title to 30,737 ordinary
shares subject to the terms of the Ryman
Healthcare Limited Employee Share
Scheme, from David William Kerr &
Warren James Bell as custodian (as bare
trustees) for the Ryman Healthcare
Limited Employee Share Scheme to
David Bennett, in accordance with such
terms
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
N/A
Number of financial products to which the transaction related: 30,737
(2)
Date of transaction:
27 August 2021
Nature of transaction:
Acquisition of beneficial interest in
51,133 ordinary shares subject to the
terms of the Ryman Healthcare Limited
Employee Share Scheme
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$750,000 (being $14.627 per share)
Number of financial products to which the transaction related: 51,133
(3)
Date of transaction:
27 August 2021
Nature of transaction: On market sale
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$449,590.10 (being $14.627 per share)
Number of financial products to which the transaction related: 30,737
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):

For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
3 September 2021
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:3 September 2021
Date of last disclosure: 8 September 2020
Director or senior manager giving disclosure
Full name(s):
Jeremy Moore
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Development Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
(1)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Beneficial owner subject to the terms of
the Ryman Healthcare Limited Employee
Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
89,653
Number held in class after acquisition or disposal:
115,191
Current registered holder(s):
David William Kerr & Warren James Bell
as custodian for the Ryman Healthcare
Limited Employee Share Scheme (as
bare trustees)
Registered holder(s) once transfers are registered:
N/A
(2)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
0
Number held in class after acquisition or disposal:
15,368
Current registered holder(s):
Jeremy Moore
Registered holder(s) once transfers are registered:
N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure-
(1)
Date of transaction:
27 August 2021
Nature of transaction:
Transfer of legal title to 15,368 ordinary
shares subject to the terms of the Ryman
Healthcare Limited Employee Share
Scheme, from David William Kerr &
Warren James Bell as custodian for the
Ryman Healthcare Limited Employee
Share Scheme to Jeremy Moore, in
accordance with such terms
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
N/A
Number of financial products to which the transaction related: 15,368
(2)
Date of transaction:
27 August 2021
Nature of transaction:
Acquisition of beneficial interest in
40,906 ordinary shares subject to the
terms of the Ryman Healthcare Limited
Employee Share Scheme
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$600,000 (being $14.627 per share)
Number of financial products to which the transaction related: 40,906
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
3 September 2021
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:3 September 2021
Date of last disclosure: 8 September 2020
Director or senior manager giving disclosure
Full name(s):
Elizabeth Cheyne Chalmers
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Operations Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
(1)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Beneficial owner subject to the terms of
the Ryman Healthcare Limited Employee
Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
40,757
Number held in class after acquisition or disposal:
81,663
Current registered holder(s):
David William Kerr & Warren James Bell
as custodian for the Ryman Healthcare
Limited Employee Share Scheme (as
bare trustees)
Registered holder(s) once transfers are registered:
N/A
(2)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
1,474
Number held in class after acquisition or disposal:
1,474
Current registered holder(s):
Elizabeth Cheyne Chalmers
Registered holder(s) once transfers are registered:
N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
(1)
Date of transaction:
27 August 2021
Nature of transaction:
Acquisition of beneficial interest in
40,906 ordinary shares subject to the
terms of the Ryman Healthcare Limited
Employee Share Scheme
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$600,000 (being $14.627 per share)
Number of financial products to which the transaction related: 40,906
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
3 September 2021
or
Signature of person authorised to sign on behalf of director or officer:

Date of signature:
Name and title of authorised person:
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:3 September 2021
Date of last disclosure: 8 September 2020
Director or senior manager giving disclosure
Full name(s):
Mary-Anne Stone
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Strategy Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
(1)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Beneficial owner subject to the terms of
the Ryman Healthcare Limited Employee
Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
22,231
Number held in class after acquisition or disposal:
63,137
Current registered holder(s):
David William Kerr & Warren James Bell
as custodian for the Ryman Healthcare
Limited Employee Share Scheme (as bare
trustees)
Registered holder(s) once transfers are registered:
N/A
(2)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
1,486
Number held in class after acquisition or disposal:
1,486
Current registered holder(s):
Mary-Anne Stone
Registered holder(s) once transfers are registered:
N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
(1)
Date of transaction:
27 August 2021
Nature of transaction:
Acquisition of beneficial interest in 40,906
ordinary shares subject to the terms of the
Ryman Healthcare Limited Employee
Share Scheme
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$600,000 (being $14.627 per share)
Number of financial products to which the transaction related: 40,906
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
3 September 2021
or
Signature of person authorised to sign on behalf of director or officer:

Date of signature:
Name and title of authorised person:
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:3 September 2021
Date of last disclosure: N/A
Director or senior manager giving disclosure
Full name(s):
Christopher Evans
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Construction Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
(1)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Beneficial owner subject to the terms of
the Ryman Healthcare Limited Employee
Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
0
Number held in class after acquisition or disposal:
40,906
Current registered holder(s):
David William Kerr & Warren James Bell
as custodian for the Ryman Healthcare
Limited Employee Share Scheme (as bare
trustees)
Registered holder(s) once transfers are registered:
N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
(1)
Date of transaction:
27 August 2021

Nature of transaction:
Acquisition of beneficial interest in 40,906
ordinary shares subject to the terms of the
Ryman Healthcare Limited Employee
Share Scheme
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$600,000 (being $14.627 per share)
Number of financial products to which the transaction related: 40,906
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
3 September 2021
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes

Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:3 September 2021
Date of last disclosure: N/A
Director or senior manager giving disclosure
Full name(s):
Cameron Holland
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Executive Officer - Australia
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
(1)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Beneficial owner subject to the terms of
the Ryman Healthcare Limited Employee
Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
0
Number held in class after acquisition or disposal:
40,906
Current registered holder(s):
David William Kerr & Warren James Bell
as custodian for the Ryman Healthcare
Limited Employee Share Scheme (as bare
trustees)
Registered holder(s) once transfers are registered:
N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
(1)
Date of transaction:
27 August 2021

Nature of transaction:
Acquisition of beneficial interest in 40,906
ordinary shares subject to the terms of the
Ryman Healthcare Limited Employee
Share Scheme
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$600,000 (being $14.627 per share)
Number of financial products to which the transaction related: 40,906
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
3 September 2021
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes

Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:3 September 2021
Date of last disclosure: N/A
Director or senior manager giving disclosure
Full name(s):
Marsha Cadman
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Sales and Marketing Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
(1)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Beneficial owner subject to the terms of
the Ryman Healthcare Limited Employee
Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
0
Number held in class after acquisition or disposal:
40,906
Current registered holder(s):
David William Kerr & Warren James Bell
as custodian for the Ryman Healthcare
Limited Employee Share Scheme (as bare
trustees)
Registered holder(s) once transfers are registered:
N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
(1)
Date of transaction:
27 August 2021

Nature of transaction:
Acquisition of beneficial interest in 40,906
ordinary shares subject to the terms of the
Ryman Healthcare Limited Employee
Share Scheme
Name of any other party or parties to the transaction (if known):N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$600,000 (being $14.627 per share)
Number of financial products to which the transaction related: 40,906
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
3 September 2021
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes

Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.